A Randomized Phase II Study of Oral Sapacitabine in Elderly Patients with Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndrome
Description: 

To evaluate 1-yr survival rate of 3 dosing schedules in elderly pts w/previously untx or 1st relapsed AML.

Study Number: 

PH 120407

Phase: 
II
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT00590187

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.